-
"I don't want to go to no stupid funeral." These words uttered by a key character in a puppet show convinced Penne Williams, LCSW, an instructor at University of South Florida at Lakeland, that the puppet show used by LifePath Hospice and Palliative Care in Tampa, FL, is exactly what is needed to help many children handle their grief.
-
Four years of a program focused on partnerships with long-term care facilities and contracts with 88 different facilities has taught the staff at Hospice Care in Madison, WI, a few tricks on how best to manage multiple relationships in different areas.
-
The Centers for Medicare & Medicaid Services (CMS) has issued a revision to Transmittal 1304 (Change Request 5567) which was titled "Reporting of Additional Data to Describe Services on Hospice Claims."
-
The following guidelines are recommended by the Drug and Food Administration (FDA) for disposal of medications.
-
Amic; Arbor Surgical Technologies; Medtronic; CV Therapeutics; Medlogics Device; St. Jude Medical; HealthTrust Purchasing Group; Masimo
-
As if a huge debt, a sagging share price, weakened sales and a variety of regulatory problems arent enough, a jury has ordered Boston Scientific (Natick, Massachusetts) to pay $431 million in damages to Dr. Bruce Saffran, a New Jersey radiologist who charged that the medical device maker's drug-eluting stents (DES) infringe a patent that he received in 1997.
-
Acacia Research; Acacia Patent Acquisition; Acrongenomics; Molecular Vision; Angiotech Pharmaceuticals; Symphony Medical; Boston Scientific; Getinge Group; Bristol-Myers Squibb; Bristol-Myers Squibb Medical Imaging; Micrus Endovascular; Genesis Medical Interventional; NewCardio; Marine Park Holdings; Synovis Life Technologies; Heraeus Vadnais
-
England's influential National Institute for Health and Clinical Excellence (NICE) has reversed its earlier position opposing use of drug-eluting stents (DES), clearing the way for reimbursement of such interventions in what is estimated to be a $100 million market. If there are no appeals against the draft decision, the final guidance on DES will go into effect in March.
-
After receiving a non-substantially equivalent letter from the FDA last month for its skin cholesterol test, Prevu, PreMD (Toronto) has now filed a request for a second level review of the 510(k) submission. "It's been devastating in terms of impact on the company," Brent Norton, president/CEO told Cardiovascular Devices & Drugs, later acknowledging that the decision puts the company in "a tough spot."
-
In an effort to better understand cardiac and other illnesses, researchers from the Université de Montréal (UdeM) said they have used a supercomputer to conduct what they believe is the largest mathematical simulation of the electrical activity of a human heart a 2-billion-element model.
